A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
C3 glomerulopathy (C3G) and primary IC-MPGN are rare kidney conditions caused by an overactive immune system. For people with these conditions who receive a kidney transplant, there is a high risk that the disease will return and damage the new donor organ. This Phase 3 study, called PRESERVE, investigates whether a medicine called pegcetacoplan can stop or delay the disease from coming back. Pegcetacoplan works by calming down a specific part of the body's immune defences. Everyone who joins will receive pegcetacoplan alongside their standard post-transplant care. Doctors will closely check how well the transplanted kidney works, look for any side effects, and see if the treatment helps the new kidney last longer. The goal is to provide better long-term protection for people receiving a kidney transplant.
At a glance
What is this study about?
C3 glomerulopathy (C3G) and primary IC-MPGN are rare, serious conditions that damage the tiny filters inside the kidneys. Over time, this damage can lead to kidney failure, meaning a person needs dialysis or a kidney transplant. While a transplant can be life-changing, these illnesses often return in the newly transplanted kidney, which can cause the new organ to fail.
Pegcetacoplan is a targeted medicine designed to control a part of the immune system called the complement system. In people with C3G and IC-MPGN, this system becomes overactive and attacks healthy kidney tissue. By blocking a specific immune protein called C3, pegcetacoplan aims to calm this harmful reaction and shield the kidney from attack.
In this study, researchers want to find out whether starting pegcetacoplan at the time of transplant surgery can prevent the disease from coming back before any new damage happens. If successful, this research could help transplant patients keep their donor kidneys working well for much longer, reducing the worry of disease recurrence and the need for further dialysis.
Key takeaways
- The PRESERVE trial tests whether pegcetacoplan can stop rare kidney diseases (C3G or IC-MPGN) returning after a transplant.
- Open to patients aged 12 and older who are preparing for a kidney transplant and are at high risk of disease recurrence.
- All participants receive the study medicine alongside their normal post-transplant treatments.
- Important vaccines against meningitis and pneumonia are required before starting the medicine to lower infection risks.
- Participation is voluntary, and taking part will not stop you from receiving standard NHS post-transplant care.
Who may be eligible?
You may be eligible to take part if you are aged 12 or older and are scheduled to receive a kidney transplant because of C3G or primary IC-MPGN. Your medical team must also consider you to be at high risk of the condition returning. This usually means you have already lost a previous donor kidney to the disease, or your doctor sees other clear medical signs that you are at high risk. You will also need to be up to date with specific routine vaccinations, including those protecting against meningitis and pneumonia.
You cannot take part if your kidney disease was triggered by another medical condition, such as hepatitis B, hepatitis C, or certain blood disorders. People who have had severe, invasive meningococcal disease in the past are also unable to join.
Additionally, you cannot join if you have had cancer within the last five years (apart from certain successfully treated skin cancers), if you have a condition called hereditary fructose intolerance, or if you have an allergy to pegcetacoplan. You also cannot take part if you have used another complement-blocking medicine in the month before your transplant.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 12 or older.
- I am scheduled to have a kidney transplant due to C3G or primary IC-MPGN.
- I am considered at high risk of the disease returning (for example, a previous donor kidney failed due to the condition).
- I am up to date with my meningitis and pneumonia vaccines (or willing to receive them).
- I have not had another complement inhibitor medicine in the past month.
- I do not have active cancer or a history of invasive meningococcal infection.
What does participation involve?
Taking part in this study means receiving pegcetacoplan in addition to your standard post-transplant medicines. Because this is an open-label study, there is no dummy drug (placebo); everyone enrolled will receive the active study medicine. You will receive the treatment by regular injections under the skin. Throughout the study, you will have regular hospital visits so doctors can check your kidney function with routine blood and urine tests, monitor your blood pressure, and perform health checks. Sometimes, a routine kidney biopsy (taking a tiny sample of kidney tissue) may be needed to check how healthy the organ is. The study team will follow your progress closely over an extended period to monitor both the safety of the medicine and how well your new kidney is working.
Potential risks and benefits
Locations (33)
- Real Hospital PortuguêsVerified postcodeRecife, Brazil· Not yet recruiting
- UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus BotucatuVerified postcodeBotucatu, Brazil· Not yet recruiting
- Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSPVerified postcodeSão Paulo, Brazil· Not yet recruiting
- University of Alberta - Faculty of Medicine & DentistryVerified postcodeEdmonton, Canada· Not yet recruiting
- St. Paul's HospitalVerified postcodeVancouver, Canada· Not yet recruiting
- London Health Sciences Centre (LHSC) - University HospitalVerified postcodeLondon, Canada· Not yet recruiting
- Toronto General HospitalVerified postcodeToronto, Canada· Not yet recruiting
- McGill University Health Centre Research InstituteVerified postcodeMontreal, Canada· Not yet recruiting
- Helsinki University Central HospitalVerified postcodeHelsinki, Finland· Not yet recruiting
- CHU Strasbourg - Nouvel Hôpital CivilVerified postcodeStrasbourg, France· Not yet recruiting
- Hopital RangueilVerified postcodeToulouse, France· Not yet recruiting
- Hopital Lapeyronie ptVerified postcodeMontpellier, France· Not yet recruiting
Common questions
Will I definitely receive the study medicine?
Yes. This is an open-label study without a placebo, meaning every person who joins will receive pegcetacoplan alongside their standard transplant care.
Why do I need vaccinations before taking part?
Pegcetacoplan calms down a part of your immune system that helps fight specific bacterial infections, including meningitis. Having your vaccines beforehand gives your body vital protection.
Do I still take my regular transplant medicines?
Yes. Pegcetacoplan is given in addition to standard post-transplant care, so you will still take your usual medicines to stop your body rejecting the organ.
Can teenagers join this study?
Yes, young people aged 12 and older can take part, provided they meet all the health criteria and have parental or guardian consent.
What happens if I change my mind?
You can leave the study at any time without giving a reason. Your medical team will simply continue providing your standard post-transplant care.
How to find out more
Study Physician
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.